Intravesical Therapy of Interstitial Cystitis

  • Philip HannoEmail author


Flashback to 1989. Bladder Pain Syndrome/Interstitial Cystitis was treated with a variety of off-label therapies, but the standard treatment against which all therapies were measured was intravesical lavage. Dimethyl sulfoxide (DMSO) had been approved a decade earlier (1978) for treatment of interstitial cystitis and remains to this day the only approved intravesical medication for the disorder by the Food and Drug Administration (FDA). Its use for this condition can be credited to Bruce Stewart of the Cleveland Clinic who persisted with an intravesical trial after failing in a transdermal clinical study of refractory patients in the mid-1960’s. It would be 1996 before sodium pentosan polysulfate became only the second approved medication and sole oral approved therapy for the syndrome.


Interstitial Cystitis Intravesical Therapy Sodium Pentosan Polysulfate Bladder Pain Approved Medications 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lübbert M, Kyereme J, Schöbel N, Beltrán L, Wetzel CH, Hatt H. Transient receptor potential channels encode volatile chemicals sensed by rat trigeminal ganglion neurons. PLoS One. 2013;8(10):e77998.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Montgomery BD, Boorjian SA, Ziegelmann MJ, Joyce DD, Linder BJ. Intravesical silver nitrate for refractory hemorrhagic cystitis. Turk J Urol. 2016;42(3):197–201.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Jerkins GR, Noe HN, Hill DE. An unusual complication of silver nitrate treatment of hemorrhagic cystitis: case report. J Urol. 1986;136(2):456–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Kojima Y, Uchida K, Takiuchi H, Wakatsuki A, Sakurai T, Fujita Y, et al. Argyrosis of the urinary tract after silver nitrate instillation: report of a case. Hinyokika Kiyo. 1993;39(1):41–4.PubMedGoogle Scholar
  5. 5.
    Kreder K, Lutgendorf S, Knopf MA, McGillis JP. Chlorpactin instillation releases calcitonin gene-related peptide in interstitial cystitis patients. Urology. 2001;57(6 Suppl 1):128–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Nickel JC, Downey J, Morales A, Emerson L, Clark J. Relative efficacy of various exogenous glycosaminoglycans in providing a bladder surface permeablility barrier. J Urol. 1998;160:612–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Hanno PM, Fritz R, Wein AJ. Heparin as an antibacterial agent in rabbit bladder. Urology. 1978;12:411–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Lane DA, Adams L. Non-anticoagulant uses of heparin. N Engl J Med. 1993;329:129–30.CrossRefPubMedGoogle Scholar
  9. 9.
    Weaver RG, Dougherty TF, Natoli CA. Recent concepts of interstitial cystitis. J Urol. 1963;89:377–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Caulfield J, Phillips R, Steinhardt G. Intravesical heparin instillation: is there systemic absorption? J Urol. 1995;153:289A.Google Scholar
  11. 11.
    Lose G, Frandsen B, Hojensgard JC, Jespersen J, Astrup T. Chronic interstitial cystitis: increased levels of eosinophil cationic protein in serum and urine and an ameliorating effect of subcutaneous heparin. Scand J Urol Nephrol. 1983;17(2):159–61.CrossRefPubMedGoogle Scholar
  12. 12.
    Lose G, Jespersen J, Frandsen B, Hojensgard JC, Astrup T. Subcutaneous heparin in the treatment of interstitial cystitis. Scand J Urol Nephrol. 1985;19(1):27–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Perez-Marrero R, Emerson LE, Maharajh DO, et al. Prolongation of response to DMSO by heparin maintenance. Urology. 1993;41(suppl):64–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994;73(5):504–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Kuo HC. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis. J Formos Med Assoc. 2001;100(5):309–14.PubMedGoogle Scholar
  16. 16.
    Parsons CL. Interstitial cystitis: new concepts in pathogenesis, diagnosis, and management. AUA News. 5(4):20–31.Google Scholar
  17. 17.
    Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology. 2005;65(1):45–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71(1):67–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103(7):910–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Nomiya A, Naruse T, Niimi A, Nishimatsu H, Kume H, Igawa Y, Homma Y. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urol. 2013;20(11):1118–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Parsons CL, Koziol JA, Proctor JG, Zupkas P, Argade S. Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms. Can J Urol. 2015;22(2):7739–44.PubMedGoogle Scholar
  22. 22.
    Gülpınar O, Kayış A, Süer E, Gökçe Mİ, Güçlü AG, Arıkan N. Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis. Can Urol Assoc J. 2014;8(9–10):E610–4.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cervigni M. Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol. 2015;4(6):638–42.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Pyo JS, Cho WJ. Systematic review and meta-analysis of intravesical hyaluronic acid and hyaluronic acid/chondroitin sulfate instillation for interstitial cystitis/painful bladder syndrome. Cell Physiol Biochem. 2016;39(4):1618–25.CrossRefPubMedGoogle Scholar
  25. 25.
    Lazzeri M, Hurle R, Casale P, Buffi N, Lughezzani G, Fiorini G, et al. Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence. Ther Adv Urol. 2016;8(2):91–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Cervigni M, Sommariva M, Tenaglia R. A randomized open label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethly sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2017;36(4):1178–86.CrossRefPubMedGoogle Scholar
  27. 27.
    Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans--a review. Neurourol Urodyn. 2013;32(1):9–18.CrossRefPubMedGoogle Scholar
  28. 28.
    Chintea CL, Belal M. Is there enough evidence for the use of intravesical instillations of glycosaminoglycan analogues in interstitial cystitis? BJU Int. 2013;111(2):192–3.CrossRefPubMedGoogle Scholar
  29. 29.
    Zeidman EJ, Helfrick B, Pollard C, Thompson IM. Bacillus calmette-guerin immunotherapy for refractory interstitial cystitis. Urology. 1994;43(1):121–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Peters K, Diokno A, Steinert B, Yuhico M, Mitchell B, Krohta S, et al. The efficacy of intravesical tice strain bacillus calmette-guerin in the treatment of interstitial cystitis: a double-blind, prospective, placebo controlled trial. J Urol. 1997;157(6):2090–4.CrossRefPubMedGoogle Scholar
  31. 31.
    Peters KM, Diokno AC, Steinert BW, Gonzalez JA. The efficacy of intravesical bacillus calmette-guerin in the treatment of interstitial cystitis: long-term followup. J Urol. 1998;159(5):1483–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Peters KM, Diokno AC, Steinert BW. Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille calmette-guerin treat interstitial cystitis by altering the immune profile in the bladder? Urology. 1999;54(3):450–3.CrossRefPubMedGoogle Scholar
  33. 33.
    Peeker R, Haghsheno MA, Holmang S, Fall M. Intravesical bacillus calmette-guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000;164(6):1912–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Propert K, Mayer R, Nickel C, Peters K, Teal V, Burks D, et al. Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus calmette-guerin or placebo. J Urol. 2008;179(2):552–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Propert KJ, Mayer R, Nickel JC, Payne CK, Peters KM, Teal V, et al. Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus calmette-guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus calmette-guerin? J Urol. 2007;178(3 Pt 1):886–90.CrossRefPubMedGoogle Scholar
  36. 36.
    Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, et al. A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol. 2005;173(4):1186–91.CrossRefPubMedGoogle Scholar
  37. 37.
    Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol. 1999;162:3–11.CrossRefPubMedGoogle Scholar
  38. 38.
    Lazzeri M, Beneforti P, Benaim G, Maggi CA, Lecci A, Turini D. Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J Urol. 1996;156:947–52.CrossRefPubMedGoogle Scholar
  39. 39.
    Lazzeri M, Beneforti P, Turini D, Barbagli G, Palminteri E. Single dose of intravesical resiniferatoxin for the treatment of interstitial cystitis -- preliminary results of a randomised controlled study. J Urol. 2000;163S:60.Google Scholar
  40. 40.
    Cruz F, Guimaraes M, Silva C, Rio ME, Coimbra A, Reis M. Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. J Urol. 1997;157:585–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE, Antoci JP, et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol. 2005;173(5):1590–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Ham BK, Kim JH, Oh MM, Lee JG, Bae JH. Effects of combination treatment of intravesical resiniferatoxin instillation and hydrodistention in patients with refractory painful bladder syndrome/interstitial cystitis: a pilot study. Int Neurourol J. 2012;16(1):41–6.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Peng CH, Kuo HC. Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis. Urol Int. 2007;78(1):78–81.CrossRefPubMedGoogle Scholar
  44. 44.
    Lee WC, Chuang YC, Lee WC, Chiang PH. Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome. Kaohsiung J Med Sci. 2011;27(10):437–40.CrossRefPubMedGoogle Scholar
  45. 45.
    Fraser MO, Chuang YC, Tyagi P, Yokoyama T, Yoshimura N, Huang L, et al. Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. Urology. 2003;61(3):656–63.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Stanford University School of MedicineStanfordUSA

Personalised recommendations